← back to search

Shengtao Yuan

China Pharmaceutical University · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research focused on Cancer research and Apoptosis, with related work in Breast cancer, Cancer, Cell cycle. Notable publications include 'PLOD2 in cancer research', 'The comprehensive landscape of miR-34a in cancer research', and 'Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells'.
h-index
citations
410
works
10
NIH funding
primary concept
email

Recent publications

Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis
Journal of Cancer 2024cited by 7position: middledoi
Arnicolide C Suppresses Tumor Progression by Targeting 14-3-3θ in Breast Cancer
Pharmaceuticals 2024cited by 3position: middledoi
Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells
World Journal of Surgical Oncology 2022cited by 58position: middledoi
The comprehensive landscape of miR-34a in cancer research
Cancer and Metastasis Reviews 2021cited by 84position: middledoi
TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma
Biochemical and Biophysical Research Communications 2021cited by 44position: middledoi
Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner
Cell Death and Disease 2020cited by 34position: middledoi
Sepiapterin reductase: Characteristics and role in diseases
Journal of Cellular and Molecular Medicine 2020cited by 32position: middledoi
Design, Synthesis, and Biological Evaluation of Novel Biotinylated Podophyllotoxin Derivatives as Potential Antitumor Agents
Frontiers in Chemistry 2019cited by 21position: middledoi
PLOD2 in cancer research
Biomedicine & Pharmacotherapy 2017cited by 104position: middledoi
Chemical Constituents from Leaves of Camellia nitidissima and Their Potential Cytotoxicity on SGC7901 Cells
Chinese Herbal Medicines 2016cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Li Sun · Harbin Medical University6 papers (2017–2024)Hongzhi Du · China Pharmaceutical University4 papers (2017–2022)Meixiao Zhan · Second Affiliated Hospital of Guangzhou Medical University3 papers (2020–2022)Jian Ding · Fudan University3 papers (2020–2024)Peng Chen · Guangzhou University of Chinese Medicine3 papers (2020–2021)Yao Wu · Jilin University2 papers (2020–2020)Danyu Du · China Pharmaceutical University2 papers (2020–2021)Ligong Lu · Jinan University2 papers (2020–2022)Yan Yuan · Southern Medical University2 papers (2024–2024)Siman Xie · Nantong University2 papers (2024–2024)Benteng Zhang · Nantong University2 papers (2024–2024)Zujue Cheng · Nanchang University2 papers (2020–2021)Jiang‐Miao Hu · Harvard Stem Cell Institute2 papers (2016–2019)Xiaoying Hou · China Pharmaceutical University2 papers (2017–2022)Zhengrui Liu · China Pharmaceutical University2 papers (2024–2024)Hong Yu · First Affiliated Hospital of Xi'an Jiaotong University2 papers (2024–2024)Zhong‐Tao Ding · Kunming University of Science and Technology1 papers (2019–2019)Li Sun · China Pharmaceutical University1 papers (2024–2024)Huaizi Fu · China Pharmaceutical University1 papers (2024–2024)Yi Jin · Fudan University1 papers (2019–2019)